Legal status · United States
Is OSK Partial Reprogramming legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. OSK Partial Reprogramming is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 1 human study is cited on its profile.
OSK Partial Reprogramming in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| FDA approval status | Not approved in any country for any indication. No reprogramming therapy has ever been approved. One investigational product, Life Biosciences ER-100, is in a recruiting phase 1 safety study (NCT07290244). |
| Human studies cited | 1 of 6 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the OSK Partial Reprogramming profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
OSK Partial Reprogramming is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What OSK Partial Reprogramming is
Three of the four Yamanaka factors, switched on briefly to reset epigenetic marks without erasing cell identity. Every efficacy result is in mice. One phase 1 safety trial is recruiting, in 18 people, in one eye.
Partial reprogramming is the idea that ageing cells keep a readable record of their younger epigenetic state, and that turning on a subset of the Yamanaka factors for a short period can recover it. OSK is that subset: Oct4, Sox2 and Klf4, with c-Myc deliberately left out because c-Myc is an oncogene.
Mechanism: Established in mice. OSK expression drives partial erasure and rewriting of DNA methylation marks, moving the methylation profile of a cell toward a younger pattern without progressing to pluripotency.
Regulatory history: Not approved in any country for any indication. No reprogramming therapy has ever been approved. One investigational product, Life Biosciences ER-100, is in a recruiting phase 1 safety study (NCT07290244).
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for OSK Partial Reprogramming at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
OSK Partial Reprogramming in other countries
United Kingdom
Not approvedInvestigational, not licensed
Is OSK Partial Reprogramming legal in the United Kingdom?Australia
Not approvedInvestigational, not registered
Is OSK Partial Reprogramming legal in Australia?Canada
Not approvedInvestigational, not approved
Is OSK Partial Reprogramming legal in Canada?Frequently asked questions
Is OSK Partial Reprogramming legal in the United States?
No. OSK Partial Reprogramming is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 1 human study is cited on its profile.
Can I buy OSK Partial Reprogramming in the United States?
No approved product exists to buy. In the United States OSK Partial Reprogramming is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is OSK Partial Reprogramming FDA approved?
No. FDA status: Not approved in any country for any indication. No reprogramming therapy has ever been approved. One investigational product, Life Biosciences ER-100, is in a recruiting phase 1 safety study (NCT07290244).. Current US classification: "Investigational, not approved". On the evidence, 1 human study is cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for OSK Partial Reprogramming live on its compound profile.
OSK Partial Reprogramming profileThis page is general information about the regulatory status of OSK Partial Reprogramming in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.